Neutrophil Aldose Reductase Activity as a Potential Marker for Neuropathy and Cataract in Diabetes

M. T. Dent, A. Veves, S. E. Tebbs, A. M. Gonzalez, Rayaz Malik, A. J M Boulton, J. D. Ward, R. M. Wilson

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Aldose reductase activity can be measured in the neutrophil and it has been proposed that this may be a marker for risk of complications in diabetes. We have studied aldose reductase activity in neutrophil, nerve, and lens in diabetic patients undergoing sural nerve biopsy or cataract extraction. A correlation was demonstrated between lens and neutrophil aldose reductase activity (r = 0.53, p = 0.01) but no correlations were demonstrated between nerve aldose reductase activities and nerve morphometry, nerve function or neutrophil aldose reductase activity. No significant difference was found between neutrophil aldose reductase activities in groups of patients with severe neuropathy, or cataract, or no complications (24 (interquartile range 16–32) vs 24 (16–40) vs 24 (16–40) nmol NADPH min−1 108‐cells −1). In a group of 56 Type 1 diabetic patients screened within 6 years of diagnosis, multiple regression analysis failed to show any relationship between neutrophil aldose reductase activity and abnormalities of neurophysiological function. These results suggest that neutrophil aldose reductase activity cannot be used as a marker for the development of cataract or neuropathy in diabetes. 1991 Diabetes UK

Original languageEnglish
Pages (from-to)911-916
Number of pages6
JournalDiabetic Medicine
Volume8
Issue number10
DOIs
Publication statusPublished - 1991
Externally publishedYes

Fingerprint

Aldehyde Reductase
Cataract
Neutrophils
Lenses
Sural Nerve
Cataract Extraction
Diabetes Complications
NADP
Regression Analysis
Biopsy

Keywords

  • Aldose reductase
  • Cataract
  • Diabetes
  • Neuropathy
  • Neutrophil Nerve biopsy

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Dent, M. T., Veves, A., Tebbs, S. E., Gonzalez, A. M., Malik, R., Boulton, A. J. M., ... Wilson, R. M. (1991). Neutrophil Aldose Reductase Activity as a Potential Marker for Neuropathy and Cataract in Diabetes. Diabetic Medicine, 8(10), 911-916. https://doi.org/10.1111/j.1464-5491.1991.tb01529.x

Neutrophil Aldose Reductase Activity as a Potential Marker for Neuropathy and Cataract in Diabetes. / Dent, M. T.; Veves, A.; Tebbs, S. E.; Gonzalez, A. M.; Malik, Rayaz; Boulton, A. J M; Ward, J. D.; Wilson, R. M.

In: Diabetic Medicine, Vol. 8, No. 10, 1991, p. 911-916.

Research output: Contribution to journalArticle

Dent, MT, Veves, A, Tebbs, SE, Gonzalez, AM, Malik, R, Boulton, AJM, Ward, JD & Wilson, RM 1991, 'Neutrophil Aldose Reductase Activity as a Potential Marker for Neuropathy and Cataract in Diabetes', Diabetic Medicine, vol. 8, no. 10, pp. 911-916. https://doi.org/10.1111/j.1464-5491.1991.tb01529.x
Dent, M. T. ; Veves, A. ; Tebbs, S. E. ; Gonzalez, A. M. ; Malik, Rayaz ; Boulton, A. J M ; Ward, J. D. ; Wilson, R. M. / Neutrophil Aldose Reductase Activity as a Potential Marker for Neuropathy and Cataract in Diabetes. In: Diabetic Medicine. 1991 ; Vol. 8, No. 10. pp. 911-916.
@article{318ee7fa7bba4a9aaabb62e7aa1a9b96,
title = "Neutrophil Aldose Reductase Activity as a Potential Marker for Neuropathy and Cataract in Diabetes",
abstract = "Aldose reductase activity can be measured in the neutrophil and it has been proposed that this may be a marker for risk of complications in diabetes. We have studied aldose reductase activity in neutrophil, nerve, and lens in diabetic patients undergoing sural nerve biopsy or cataract extraction. A correlation was demonstrated between lens and neutrophil aldose reductase activity (r = 0.53, p = 0.01) but no correlations were demonstrated between nerve aldose reductase activities and nerve morphometry, nerve function or neutrophil aldose reductase activity. No significant difference was found between neutrophil aldose reductase activities in groups of patients with severe neuropathy, or cataract, or no complications (24 (interquartile range 16–32) vs 24 (16–40) vs 24 (16–40) nmol NADPH min−1 108‐cells −1). In a group of 56 Type 1 diabetic patients screened within 6 years of diagnosis, multiple regression analysis failed to show any relationship between neutrophil aldose reductase activity and abnormalities of neurophysiological function. These results suggest that neutrophil aldose reductase activity cannot be used as a marker for the development of cataract or neuropathy in diabetes. 1991 Diabetes UK",
keywords = "Aldose reductase, Cataract, Diabetes, Neuropathy, Neutrophil Nerve biopsy",
author = "Dent, {M. T.} and A. Veves and Tebbs, {S. E.} and Gonzalez, {A. M.} and Rayaz Malik and Boulton, {A. J M} and Ward, {J. D.} and Wilson, {R. M.}",
year = "1991",
doi = "10.1111/j.1464-5491.1991.tb01529.x",
language = "English",
volume = "8",
pages = "911--916",
journal = "Diabetic Medicine",
issn = "0742-3071",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Neutrophil Aldose Reductase Activity as a Potential Marker for Neuropathy and Cataract in Diabetes

AU - Dent, M. T.

AU - Veves, A.

AU - Tebbs, S. E.

AU - Gonzalez, A. M.

AU - Malik, Rayaz

AU - Boulton, A. J M

AU - Ward, J. D.

AU - Wilson, R. M.

PY - 1991

Y1 - 1991

N2 - Aldose reductase activity can be measured in the neutrophil and it has been proposed that this may be a marker for risk of complications in diabetes. We have studied aldose reductase activity in neutrophil, nerve, and lens in diabetic patients undergoing sural nerve biopsy or cataract extraction. A correlation was demonstrated between lens and neutrophil aldose reductase activity (r = 0.53, p = 0.01) but no correlations were demonstrated between nerve aldose reductase activities and nerve morphometry, nerve function or neutrophil aldose reductase activity. No significant difference was found between neutrophil aldose reductase activities in groups of patients with severe neuropathy, or cataract, or no complications (24 (interquartile range 16–32) vs 24 (16–40) vs 24 (16–40) nmol NADPH min−1 108‐cells −1). In a group of 56 Type 1 diabetic patients screened within 6 years of diagnosis, multiple regression analysis failed to show any relationship between neutrophil aldose reductase activity and abnormalities of neurophysiological function. These results suggest that neutrophil aldose reductase activity cannot be used as a marker for the development of cataract or neuropathy in diabetes. 1991 Diabetes UK

AB - Aldose reductase activity can be measured in the neutrophil and it has been proposed that this may be a marker for risk of complications in diabetes. We have studied aldose reductase activity in neutrophil, nerve, and lens in diabetic patients undergoing sural nerve biopsy or cataract extraction. A correlation was demonstrated between lens and neutrophil aldose reductase activity (r = 0.53, p = 0.01) but no correlations were demonstrated between nerve aldose reductase activities and nerve morphometry, nerve function or neutrophil aldose reductase activity. No significant difference was found between neutrophil aldose reductase activities in groups of patients with severe neuropathy, or cataract, or no complications (24 (interquartile range 16–32) vs 24 (16–40) vs 24 (16–40) nmol NADPH min−1 108‐cells −1). In a group of 56 Type 1 diabetic patients screened within 6 years of diagnosis, multiple regression analysis failed to show any relationship between neutrophil aldose reductase activity and abnormalities of neurophysiological function. These results suggest that neutrophil aldose reductase activity cannot be used as a marker for the development of cataract or neuropathy in diabetes. 1991 Diabetes UK

KW - Aldose reductase

KW - Cataract

KW - Diabetes

KW - Neuropathy

KW - Neutrophil Nerve biopsy

UR - http://www.scopus.com/inward/record.url?scp=0025721864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025721864&partnerID=8YFLogxK

U2 - 10.1111/j.1464-5491.1991.tb01529.x

DO - 10.1111/j.1464-5491.1991.tb01529.x

M3 - Article

VL - 8

SP - 911

EP - 916

JO - Diabetic Medicine

JF - Diabetic Medicine

SN - 0742-3071

IS - 10

ER -